Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Njei B, Al-Ajlouni Y, Lemos S, Ugwendum D, Ameyaw P, Njei L, Boateng S. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cureus 2024, 16: e71366. PMID: 39534801, PMCID: PMC11556413, DOI: 10.7759/cureus.71366.Peer-Reviewed Original ResearchRandomized Controlled TrialsGLP-1RAsReceptor agonistsSafety of GLP-1 receptor agonistsLiver functionLiver diseaseGlucagon-like peptide-1 receptor agonistsMeta-analysis of randomized controlled trialsSteatotic liver diseasePeptide-1 receptor agonistsControlled TrialsGLP-1 receptor agonistsMeta-analysisMeta-analyze randomized controlled trialsRevised Cochrane Risk of Bias ToolAssociated with significant reductionsPromote weight lossImprove liver functionCardiovascular risk factorsCochrane risk of bias toolRisk of bias toolRandom-effects modelHepatic outcomesHepatic function markersGLP-1RA
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply